Compare Stocks: UG, NRXP, VTVT, and UNCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NRXP NRx Pharmaceuticals	$2.70 -5.3%	$3.26	$1.62 ▼ $5.05	$123.39M	2.07	660,149 shs	552,507 shs
UG United-Guardian	$6.86 -0.6%	$7.14	$5.58 ▼ $8.45	$31.70M	0.95	10,178 shs	9,034 shs
UNCY Unicycive Therapeutics	$3.73 -7.9%	$4.96	$3.67 ▼ $8.74	$112.81M	1.83	918,363 shs	1.84 million shs
VTVT vTv Therapeutics	$28.23 -7.3%	$31.90	$19.50 ▼ $44.00	$119.98M	0.21	38,378 shs	41,764 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NRXP NRx Pharmaceuticals	-5.26%	-8.16%	-20.59%	-39.46%	-13.46%
UG United-Guardian	-0.58%	-4.46%	-4.32%	-5.77%	-8.53%
UNCY Unicycive Therapeutics	-7.90%	-11.82%	-29.49%	-25.70%	-16.93%
VTVT vTv Therapeutics	-7.32%	-5.99%	-11.70%	-13.64%	+29.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NRXP NRx Pharmaceuticals	$2.70 -5.3%	$3.26	$1.62 ▼ $5.05	$123.39M	2.07	660,149 shs	552,507 shs
UG United-Guardian	$6.86 -0.6%	$7.14	$5.58 ▼ $8.45	$31.70M	0.95	10,178 shs	9,034 shs
UNCY Unicycive Therapeutics	$3.73 -7.9%	$4.96	$3.67 ▼ $8.74	$112.81M	1.83	918,363 shs	1.84 million shs
VTVT vTv Therapeutics	$28.23 -7.3%	$31.90	$19.50 ▼ $44.00	$119.98M	0.21	38,378 shs	41,764 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NRXP NRx Pharmaceuticals	-5.26%	-8.16%	-20.59%	-39.46%	-13.46%
UG United-Guardian	-0.58%	-4.46%	-4.32%	-5.77%	-8.53%
UNCY Unicycive Therapeutics	-7.90%	-11.82%	-29.49%	-25.70%	-16.93%
VTVT vTv Therapeutics	-7.32%	-5.99%	-11.70%	-13.64%	+29.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	1,177.78% Upside
UG United-Guardian	2.00	Hold	N/A	N/A
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.25	389.28% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	97.78% Upside

Current Analyst Ratings Breakdown

Latest UG, NRXP, VTVT, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$15.00 ➝ $13.00
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/4/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/18/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NRXP NRx Pharmaceuticals	$1.23M	95.05	N/A	N/A	($0.54) per share	-5.00
UG United-Guardian	$10.55M	2.98	$0.48 per share	14.32	$2.44 per share	2.81
UNCY Unicycive Therapeutics	$680K	152.77	N/A	N/A	$1.41 per share	2.65
VTVT vTv Therapeutics	$1.02M	109.05	N/A	N/A	$16.36 per share	1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
UG United-Guardian	$2.11M	$0.54	12.78	N/A	N/A	22.01%	22.24%	19.12%	N/A
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	1.95	N/A	N/A	-91.50%	-61.47%	11/11/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest UG, NRXP, VTVT, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	N/A	UNCY Unicycive Therapeutics	-$0.33	N/A	N/A	N/A	$0.90 million	N/A
11/5/2026	Q3 2026	VTVT vTv Therapeutics	-$1.16	N/A	N/A	N/A	$0.33 million	N/A
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A
8/7/2026	Q2 2026	UG United-Guardian	N/A	$0.16	N/A	$0.16	N/A	$3.11 million
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$0.60	8.75%	-5.11%	111.11%	1 Years
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest UG, NRXP, VTVT, and UNCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/14/2026	UG United-Guardian		$0.30	8.19%	7/28/2026	7/28/2026	8/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
UG United-Guardian	N/A	7.32	6.64
UNCY Unicycive Therapeutics	N/A	3.81	3.81
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NRXP NRx Pharmaceuticals	4.27%
UG United-Guardian	23.16%
UNCY Unicycive Therapeutics	40.42%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
NRXP NRx Pharmaceuticals	6.40%
UG United-Guardian	29.00%
UNCY Unicycive Therapeutics	6.03%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable
UG United-Guardian	25	4.59 million	3.26 million	Not Optionable
UNCY Unicycive Therapeutics	22	27.85 million	26.18 million	Not Optionable
VTVT vTv Therapeutics	26	3.94 million	3.70 million	Not Optionable

UG, NRXP, VTVT, and UNCY Headlines

Recent News About These Companies

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

October 10, 2026 | markets.businessinsider.com

Millennium Management and Israel Englander Reveal 8.7% Stake in vTv Therapeutics

October 9, 2026 | kalkinemedia.comK

vTv Therapeutics stock jumps on FDA orphan drug status

October 8, 2026 | uk.finance.yahoo.com

Analysts Conflicted on These Healthcare Names: vTv Therapeutics (VTVT) and CSL (OtherCMXHF)

October 8, 2026 | theglobeandmail.com

VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease

October 8, 2026 | rttnews.com

FDA grants orphan drug status to vTv Therapeutics' sickle cell drug

October 8, 2026 | streetinsider.com

Contrasting Milestone Pharmaceuticals (NASDAQ:MIST) and vTv Therapeutics (NASDAQ:VTVT)

October 8, 2026 | americanbankingnews.com

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

October 7, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 7, 2026 | americanbankingnews.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from Brokerages

October 7, 2026 | marketbeat.com

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

October 6, 2026 | globenewswire.com

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

October 5, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

October 3, 2026 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Upgraded to Hold at Wall Street Zen

October 3, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened

September 23, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 15, 2026

September 15, 2026 | biospace.comB

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 15, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UG, NRXP, VTVT, and UNCY Company Descriptions

NRx Pharmaceuticals NASDAQ:NRXP

$2.70 -0.15 (-5.26%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$2.73 +0.03 (+1.11%)

As of 10/13/2026 07:30 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

United-Guardian NASDAQ:UG

$6.86 -0.04 (-0.58%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$6.82 -0.04 (-0.66%)

As of 10/13/2026 07:30 PM Eastern

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

Unicycive Therapeutics NASDAQ:UNCY

$3.73 -0.32 (-7.90%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$3.75 +0.02 (+0.59%)

As of 10/13/2026 07:57 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

vTv Therapeutics NASDAQ:VTVT

$28.23 -2.23 (-7.32%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$27.76 -0.47 (-1.66%)

As of 10/13/2026 07:35 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UG, NRXP, VTVT, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UG, NRXP, VTVT, and UNCY Earnings

Compare Dividends

Latest UG, NRXP, VTVT, and UNCY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UG, NRXP, VTVT, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UG, NRXP, VTVT, and UNCY Company Descriptions

NRx Pharmaceuticals NASDAQ:NRXP

United-Guardian NASDAQ:UG

Unicycive Therapeutics NASDAQ:UNCY

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools